Search Results - "Wolka, Anne M."

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug—naive patients with type 2 diabetes: A randomized, double-blind, placebo-controlled, parallel-group study by Moretto, Thomas J., MD, Milton, Denái R., MS, Ridge, Terry D., MSN, MacConell, Leigh A., PhD, Okerson, Ted, MD, Wolka, Anne M., PhD, Brodows, Robert G., MD

“…Abstract Background: Evaluation of exenatide monotherapy in patients with type 2 diabetes may be of clinical interest based on improvements in glycemic control…”
Get full text

6-Month, Randomized, Double-Masked, Placebo-Controlled Study Evaluating the Effects of the Protein Kinase C-β Inhibitor Ruboxistaurin on Skin Microvascular Blood Flow and Other Measures of Diabetic Peripheral Neuropathy by Casellini, Carolina M, Barlow, Patricia M, Rice, Amanda L, Casey, Melissa, Simmons, Kathryn, Pittenger, Gary, Bastyr, Edward J. III, Wolka, Anne M, Vinik, Aaron I

“…OBJECTIVE:--Diabetes leads to protein kinase C (PKC)-β overactivation and microvascular dysfunction, possibly resulting in disordered skin microvascular blood…”
Get full text

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes by KADOWAKI, Takashi, NAMBA, Mitsuyoshi, YAMAMURA, Ayuko, SOWA, Hideaki, WOLKA, Anne M, BRODOWS, Robert G

“…This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by IWAMOTO, Kazuya, NASU, Risa, YAMAMURA, Ayuko, KOTHARE, Prajakti A., MACE, Kenneth, WOLKA, Anne M., LINNEBJERG, Helle

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study by Russell-Jones, David, Cuddihy, Robert M, Hanefeld, Markolf, Kumar, Ajay, González, Jose G, Chan, Melanie, Wolka, Anne M, Boardman, Marilyn K

“…OBJECTIVE: To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26…”
Get full text

Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2 by Aiello, Lloyd Paul, Vignati, Louis, Sheetz, Matthew J, Zhi, Xin, Girach, Aniz, Davis, Matthew D, Wolka, Anne M, Shahri, Nazila, Milton, Roy C

“…To evaluate efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with moderately severe to very severe nonproliferative diabetic…”
Get full text

Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia by Porst, Hartmut, McVary, Kevin T, Montorsi, Francesco, Sutherland, Peter, Elion-Mboussa, Albert, Wolka, Anne M, Viktrup, Lars

“…Abstract Background Lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH; BPH-LUTS) may be associated with erectile dysfunction…”
Get full text

What is clearance worth? Patients' stated risk tolerance for psoriasis treatments by Fairchild, Angelyn O., Reed, Shelby D., Johnson, F. Reed, Anglin, Greg, Wolka, Anne M., Noel, Rebecca A.

“…Purpose: The purpose of this study was to provide quantitative evidence of patients' tolerance for therapeutic risks associated with psoriasis treatments that…”
Get full text

Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction by Porst, Hartmut, Rajfer, Jacob, Casabé, Adolfo, Feldman, Robert, Ralph, David, Vieiralves, Luiz F., Esler, Anne, Wolka, Anne M., Klise, Suzanne R.

“…With once-daily administration of tadalafil, dosing and sexual activity would no longer need to be temporally linked for patients with erectile dysfunction…”
Get full text

Effective Partnering in Conducting Benefit-Risk Patient Preference Studies: Perspectives From a Patient Advocacy Organization, a Pharmaceutical Company, and Academic Stated-Preference Researchers by Wolka, Anne M, Fairchild, Angelyn O, Reed, Shelby D, Anglin, Greg, Johnson, F Reed, Siegel, Michael, Noel, Rebecca

“…Formal incorporation of patients' perspectives is becoming increasingly important in medical product development and decision making. This article shares…”
Get more information

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes by TAKASHI KADOWAKI, MITSUYOSHI NAMBA, AYUKO YAMAMURA, HIDEAKI SOWA, ANNE M.WOLKA, ROBERT G.BRODOWS

“…「Abstract」. This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally…”
Get full text

Safety of Growth Hormone Treatment in Pediatric Patients with Idiopathic Short Stature by Quigley, Charmian A., Gill, Anne M., Crowe, Brenda J., Robling, Kristen, Chipman, John J., Rose, Susan R., Ross, Judith L., Cassorla, Fernando G., Wolka, Anne M., Wit, Jan M., Rekers-Mombarg, Lyset T. M., Cutler, Gordon B.

“…Context: Recombinant human GH was approved by the United States Food and Drug Administration in 2003 for the treatment of idiopathic short stature (ISS)…”
Get full text

Corrigendum to “Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia” [Eur Urol 2009;56:727–36] by Porst, Hartmut, McVary, Kevin T, Montorsi, Francesco, Sutherland, Peter, Elion-Mboussa, Albert, Wolka, Anne M, Viktrup, Lars

Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by KAZUYA IWAMOTO, RISA NASU, AYUKO YAMAMURA, PRAJAKTI A.KOTHARE, KENNETH MACE, ANNE M.WOLKA, HELLE LINNEBJERG

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

Pain and the blood–brain barrier: obstacles to drug delivery by Wolka, Anne M, Huber, Jason D, Davis, Thomas P

“…Delivery of drugs across the blood–brain barrier has been shown to be altered during pathological states involving pain. Pain is a complex phenomenon involving…”
Get full text

Effect of Growth Hormone Dose on Bone Maturation and Puberty in Children with Idiopathic Short Stature by Crowe, Brenda J., Rekers-Mombarg, Lyset T. M., Robling, Kristen, Wolka, Anne M., Cutler, Gordon B., M., Jan

“…Context: GH at 0.22 mg/kg·wk has been shown to have no effect on pubertal onset or pace, whereas GH at 0.5 mg/kg·wk has been shown to advance pubertal onset…”
Get full text

The interaction of the penetration enhancer DDAIP with a phospholipid model membrane by Wolka, Anne M, Rytting, J.H, Reed, B.L, Finnin, B.C

“…Differential scanning calorimetry (DSC) was used to investigate the mechanism of action of a proprietary skin penetration enhancer, dodecyl-2-( N,…”
Get full text

Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) by Russell-Jones, David, Cuddihy, Robert M., Hanefeld, Markolf, Kumar, Ajay, González, Jose G., Chan, Melanie, Wolka, Anne M., Boardman, Marilyn K.

“…OBJECTIVE To test the safety and efficacy of exenatide once weekly (EQW) compared with metformin (MET), pioglitazone (PIO), and sitagliptin (SITA) over 26…”
Get full text

Effects of Once-Daily Tadalafil on Erectile Function in Men with Erectile Dysfunction and Signs and Symptoms of Benign Prostatic Hyperplasia. Commentary by PORST, Hartmut, MCVARY, Kevin T, MONTORSI, Francesco, SUTHERLAND, Peter, ELION-MBOUSSA, Albert, WOLKA, Anne M, VIKTRUP, Lars, VOLPE, Alessandro

Get full text

Pain and the blood-brain barrier: obstacles to drug delivery: Innovative technologies for the research and treatment of pain by WOLKA, Anne M, HUBER, Jason D, DAVIS, Thomas P

Get full text